Menu

赛诺菲喜保宁使用说明书

Author: Medicalhalo
Release time: 2025-10-19 11:44:20

Sanofi Instructions for Use

[Drug Name] Vigabatrin Tablets; Vigabatrin; SABRIL

[Indications] Adjuvant treatment of anti-epilepsy

【Preparation】500mg

[Dosage] Adults: The recommended dose is 3g per day, taken in divided doses. The dose should be increased according to the clinical effect at a rate of 0.5-1g per day to 4g per day (or 50mg/kg per day), which is effective for complex partial seizures of epilepsy (with or without generalized tonic-clonic seizures). Children: General usage: For children aged 3-9 years, the recommended dose is 1g per day, divided into 2 times; for older children, 2g per day, divided into 2 times. West syndrome: Average oral dose is 100 mg/kg daily (range 50-150 mg/kg).

[Adverse reactions] Common ones include fatigue, drowsiness, headache, dizziness, confusion and depression. Occasional aggressive behavior and psychosis (more common in patients with a history of psychosis and behavioral problems), memory loss, diplopia, weight gain, gastrointestinal disturbances, edema, and alopecia. Nystagmus, nervousness, agitation, ataxia, paresthesia, and tremor may also occur. Some patients develop irreversible visual field defects, retinal lesions such as peripheral retinal atrophy, and more rarely, optic neuritis and atrophy. Mentally, agitation, aggressive behavior, and paranoia may occur, and may occur in people with or without a history of mental illness. Mania or psychosis is also rare. Hemoglobin and transaminase values ​​may be reduced. Children may become excited and anxious.

Please read Sanofi's instructions for use carefully and use it under the guidance of a physician.

Recommended related hot articles: /newsDetail/97425.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。